Budget and Long Range Plan. Responsibility for the Budget and Long Range Plan with regard to Licensed Products, [CONFIDENTIAL TREATMENT REQUESTED], will rest with the JCC and the JDC, who will develop budgets for development and commercialization in coordination with the Joint Finance Committee, subject to final approval by the Management Committee. Responsibility for the Budget and Long Range Plan with regard to New Products, including, without limitation, G2H7, and with regard to all Franchise Products (including, without limitation, C2B8) [CONFIDENTIAL TREATMENT REQUESTED], will rest with Genentech, who will develop budgets for development and commercialization in coordination with the Joint Finance Committee, subject to final approval by the Management Committee. Budgets will be prepared annually for the following full calendar year containing monthly details/numbers. Budgets will be supplemented with high level business plans and costs for clinical trials, registration applications, and plans for product introduction, sales efforts and promotion as approved by the Joint Development Committee and Joint Commercialization Committee. Budgets, once ratified by the Management Committee, can only be changed with the approval of the Management Committee (with the exception of the provisions outlined in Sections 4.5 and 5.4(b) of the Collaboration Agreement). A five-year Long Range Plan for GenIDEC will be established on a yearly basis under the direction of the Management Committee and submitted to Genentech and IDEC by July 31st.
Budget and Long Range Plan. Responsibility for the budget and long-range plan will rest with the relevant Joint Project Team, which will develop budgets for development and commercialization for the term of the Joint Project Team, subject to final approval by the JSC. Budgets will be prepared annually. In addition, headcount chargeable to GenGain will be agreed to annually by the JSC. Budgets will be supplemented with detailed business plans for clinical trials, Regulatory Approval applications, and detailed plans for product introduction, sales efforts and promotion as determined by each Joint Project Team. Budgets, once approved by the JSC, can only be changed with the written approval of the JSC. The Joint Project Team, with the assistance of the financial representatives from Genentech and Magainin, will be responsible for identifying, analyzing and reporting all significant line item budget variances and all overall, total budget variances. Only the JSC may approve materially unfavorable line item budget variations, as defined by the Joint Project Team, and all overall, total budget variations, chargeable to GenGain during the course of any year during the term of the Agreement.
Budget and Long Range Plan. MSC will establish and maintain business processes to develop and monitor budgets, plans and long-range plans.
Budget and Long Range Plan. Responsibility for the Budget and Long Range Plan will rest with the Joint Core Team, who will develop budgets for development and commercialization in coordination with the Finance Committee, subject to final approval by the Joint Steering Committee. Budgets will be prepared annually. In addition, headcount chargeable to GenXOMA will be agreed to annually. Budgets will be supplemented with detailed business plans for clinical trials, registration applications, and detailed plans for product introduction, sales efforts and promotion as determined by the Joint Core Team. Budgets, once approved by the Joint Steering Committee, can only be changed with the approval of the Joint Steering Committee.
Budget and Long Range Plan. Budgets will be prepared annually. Responsibility for the budget and long range plan will rest with the Joint Project Team, which will develop budgets for development and commercialization, subject to final approval by the JSC. Budgets will be supplemented with detailed business plans for clinical trials, drug approval applications, and plans for product introduction, sales and promotion efforts as determined by the Joint Project Team. Budgets, once approved by the JSC, can only be changed with the approval of the JSC, as provided in the Agreement. The Joint Project Team, with the assistance of the Joint Finance Subcommittee, will be responsible for identifying, analyzing and reporting all significant line item budget variances and all overall, total budget variances. Only the JSC may approve materially unfavorable line item budget variations, as defined by the Joint Project Team, and all overall, total budget variations, chargeable to the Collaboration during the course of the year. A ** long range plan for the Collaboration will be established on a yearly basis under the direction of the JSC and submitted to Genentech and OSI by ** each year.
